HRP20090684T1 - Kondicionirani sastav krvi i metoda za njegovu proizvodnju - Google Patents

Kondicionirani sastav krvi i metoda za njegovu proizvodnju Download PDF

Info

Publication number
HRP20090684T1
HRP20090684T1 HR20090684T HRP20090684T HRP20090684T1 HR P20090684 T1 HRP20090684 T1 HR P20090684T1 HR 20090684 T HR20090684 T HR 20090684T HR P20090684 T HRP20090684 T HR P20090684T HR P20090684 T1 HRP20090684 T1 HR P20090684T1
Authority
HR
Croatia
Prior art keywords
blood
composition according
muscle
blood composition
interleukin
Prior art date
Application number
HR20090684T
Other languages
English (en)
Inventor
Reinecke Julio
Wehling Peter
Original Assignee
Orthogen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37965046&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20090684(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orthogen Ag filed Critical Orthogen Ag
Publication of HRP20090684T1 publication Critical patent/HRP20090684T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/0209—Multiple bag systems for separating or storing blood components
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

Abstract

Metoda za proizvodnju kondicioniranog sastava krvi, iz krvi, naznačena time, što sadrži korake: (a) inkubiranje krvi, koje je povučeno iz ljudskog ili životinjskog tijela, u modificiranu posudu koja ima unutarnju površinu na temperaturi od 10 do 40 °C da kondicionira krv, pri čemu su faktori inducirani; i (b) dobivanje kondicioniranog sastava krvi sa induciranim faktorima u modificiranoj posudi, pri čemu je posuda modificirana tako da ima unutarnju površinu od 200 mm? do 750 mm? po 1 ml inkubirane krvi. Patent sadrži još 35 patentnih zahtjeva.

Claims (36)

1. Metoda za proizvodnju kondicioniranog sastava krvi, iz krvi, naznačena time, što sadrži korake: (a) inkubiranje krvi, koje je povučeno iz ljudskog ili životinjskog tijela, u modificiranu posudu koja ima unutarnju površinu na temperaturi od 10 do 40 °C da kondicionira krv, pri čemu su faktori inducirani; i (b) dobivanje kondicioniranog sastava krvi sa induciranim faktorima u modificiranoj posudi, pri čemu je posuda modificirana tako da ima unutarnju površinu od 200 mm² do 750 mm² po 1 ml inkubirane krvi.
2. Metoda u skladu sa zahtjevom 1, naznačena time, što prisutnost interleukina-6 (IL-6) u sastavu krvi na udio od najmanje 30 pg po 1 ml označava uspješnu indukciju.
3. Metoda u skladu s bilo kojim prethodnim zahtjevom, naznačena time, što inkubacija postupa za period od 2 do 36 sata.
4. Metoda u skladu s bilo kojim prethodnim zahtjevom, naznačena time, što je djelomični tlak kisika (pO2) za vrijeme inkubacije manji od 5 kPa.
5. Metoda u skladu s bilo kojim prethodnim zahtjevom, naznačena time, što su u daljnjem koraku stanične komponente odvojene od kondicioniranog sastava krvi i kondicionirani sastava krvnog seruma je dobiven.
6. Metoda u skladu s bilo kojim prethodnim zahtjevom, naznačena time, što modificirana posuda ima unutarnje strukture velikih površina koje su odabrane iz sfera, vlakana, praha, zrnastog materijala, čestica, i kombinacija istih.
7. Metoda u skladu sa zahtjevom 6, naznačena time, što unutarnje strukture sadrže najmanje jedan materijal odabran iz metala, metalnih oksida i plastika kao što su staklo, korund, kvarc, polistiren, polivinilklorid, polietilen, polipropilen ili kombinacija istih.
8. Metoda u skladu s bilo kojim prethodnim zahtjevom, naznačena time, što modificirana posuda ima u svojoj unutrašnjosti staklo sfera sa promjerom od 0.5 do 5 mm.
9. Metoda u skladu s bilo kojim prethodnim zahtjevom, naznačena time, što modificirana posuda ima elastične zidove za bezzračno povlačenje krvi iz životinjskog ili ljudskog tijela.
10. Metoda u skladu sa zahtjevom 9, naznačena time, što je posuda odabrana iz vrećica krvi za transfuzijsku medicinu.
11. Metoda u skladu sa zahtjevom 10, naznačena time, što je posuda odabrana iz jednostrukih-dvostrukih-, trostrukih-, i višestrukih-vrećica sustava.
12. Metoda u skladu sa bilo kojim zahtjevom 9 do 11, naznačena time, što elastični zidovi posude imaju nisku popustljivost kisika.
13. Metoda u skladu s bilo kojim prethodnim zahtjevom, naznačena time, što je sastav krvi alogeničan.
14. Metoda u skladu s bilo kojim prethodnim zahtjevom, naznačena time, što je sastav krvi autologan.
15. Metoda u skladu s bilo kojim prethodnim zahtjevom, naznačena time, što je sastav krvi podrijelom iz člana druge vrste.
16. Sastav krvi proizvodiv metodom u skladu s bilo kojim prethodnim zahtjevom za liječenje ili preventivu bola ljudskog ili životinjskog tijela, naznačen time, što sadrži 30 do 20,000 pg/ml interleukina-6 (IL-6).
17. Sastav krvi u skladu sa zahtjevom 16, naznačen time, što sadrži najmanje jednu daljnju komponentu odabranu iz: - interleukin-1 receptor antagonista (IL-1Ra); - interleukin-4 (IL-4); - interleukin-13 (IL-13); - interleukin-1 (IL-1); - interleukin 10 (IL-10); - čimbenika nekroze tumora (TNF); - inzulina sličan faktora rasta (IGF); - transformirajućeg faktora rasta (TGF); - faktora rasta izvedenog od trombocita (PDGF); - fibroblasta faktora rasta (FGF); i - hepatocitnog faktora rasta (HGF).
18. Sastav krvi u skladu sa zahtjevom 16 ili 17, naznačen time, što dalje sadrži barem jednu komponentu odabranu iz vesikula, mikro-vesikula, eksosoma, iRNA i smjese istih.
19. Sastav krvi u skladu sa zahtjevom 16 do 18, naznačen time, što je interleukin-1 receptor antagonist (IL-1Ra) prisutan u iznosu od 30 - 50,000 pg/ml.
20. Sastav krvi u skladu sa zahtjevom 16 do 19, naznačen time, što je interleukin-4 (IL-4) prisutan u iznosu od 2 - 100 pg/ml.
21. Sastav krvi u skladu sa bilo kojim zahtjevom 16 do 20, naznačen time, što je interleukin-13 (IL-13) prisutan u iznosu od 2 - 100 pg/ml.
22. Sastav krvi u skladu sa bilo kojim zahtjevom 16 do 21, naznačen time, što je interleukin-1 (IL-1) prisutan u iznosu od 5 - 1,000 pg/ml.
23. Sastav krvi u skladu sa bilo kojim zahtjevom 16 do 22, naznačen time, što je interleukin-10 (IL-10) prisutan u iznosu od 5 - 1,000 pg/ml.
24. Sastav krvi u skladu sa bilo kojim zahtjevom 16 do 23, naznačen time, što je čimbenik nekroze tumora (TNF) prisutan u iznosu od 5 - 1,000 pg/ml.
25. Sastav krvi u skladu sa bilo kojim zahtjevom 16 do 24, naznačen time, što je inzulin sličan faktoru rasta (IGF) prisutan u iznosu od 100 - 15,000 pg/ml.
26. Sastav krvi u skladu sa bilo kojim zahtjevom 16 do 25, naznačen time, što je transformirajući faktor rasta (TGF) prisutan u iznosu od 10 - 20,000 pg/ml.
27. Sastav krvi u skladu sa bilo kojim zahtjevom 16 do 26, naznačen time, što je faktor rasta izveden od trombocita (PDGF) prisutan u iznosu od 100 - 10,000 pg/ml.
28. Sastav krvi u skladu sa bilo kojim zahtjevom 16 do 27, naznačen time, što je fibroblast faktora rasta (FGF) prisutan u iznosu od 50 - 10,000 pg/ml.
29. Sastav krvi u skladu sa bilo kojim zahtjevom 16 do 28, naznačen time, što je hepatocitni faktor rasta (HGF) prisutan u iznosu od 10 - 10,000 pg/ml.
30. Sastav krvi u skladu sa bilo kojim zahtjevom 16 do 29, naznačen time, što je za liječenje ili preventivu boli ljudskog ili životinjskog tijela odabran iz: - bolesti mišića; - žilnih bolesti; - alergija; - netolerancija hrane; - netolerancija lijekova; - bolesti uključujući imunološki sustav; - psorijaze; i - kronične rane kao dijabetski čirevi.
31. Sastav krvi u skladu sa zahtjevom 30, naznačen time, što je bolest mišića ozljeda mišića, operacija mišića, rascjep mišićnih vlakana, degeneracija mišića, defekt mišića, atrofija mišića, mišićna kila, mišićna distrofija, umor mišića ili bol mišića.
32. Sastav krvi u skladu sa bilo kojim zahtjevom 30 ili 31, naznačen time, što liječenje bolesti mišića uključuje regeneraciju mišićnog tkiva.
33. Sastav krvi u skladu sa bilo kojim zahtjevom 16 do 29, naznačen time, što je za liječenje ili preventivu bolova ljudskog ili životinjskog tijela odabran iz: - neurodermatitisa; - upale i iritacije živčanog sustava; - endometrioze; - kronične upale oka kod konja.
34. Sastav krvi u skladu sa bilo kojim zahtjevom 30 do 33, naznačen time, što je injektiran u tijelo ili povrijeđeni organ, opcionalno zajedno sa farmaceutskim pomoćnim tvarima.
35. Upotreba sastava krvi u skladu sa bilo kojim zahtjevom 16 do 29, naznačena time, što je za proizvodnju lijeka za liječenje ili preventivu bolova ljudskog ili životinjskog tijela karakterizirana u zahtjevima 30 do 33.
36. Upotreba sastava krvi u skladu sa bilo kojim zahtjevom 16 do 29, naznačena time, što je kozmetički proizvod.
HR20090684T 2006-02-03 2009-12-23 Kondicionirani sastav krvi i metoda za njegovu proizvodnju HRP20090684T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006005016A DE102006005016A1 (de) 2006-02-03 2006-02-03 Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung
PCT/EP2007/000903 WO2007090569A1 (de) 2006-02-03 2007-02-02 Konditionierte blutzusammensetzung und verfahren zu deren herstellung

Publications (1)

Publication Number Publication Date
HRP20090684T1 true HRP20090684T1 (hr) 2010-02-28

Family

ID=37965046

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20090684T HRP20090684T1 (hr) 2006-02-03 2009-12-23 Kondicionirani sastav krvi i metoda za njegovu proizvodnju

Country Status (24)

Country Link
US (1) US20090047242A1 (hr)
EP (2) EP2156841A1 (hr)
JP (1) JP2009525297A (hr)
KR (1) KR20080100425A (hr)
CN (1) CN101378768A (hr)
AT (1) ATE446100T1 (hr)
AU (1) AU2007213996A1 (hr)
BR (1) BRPI0707360A2 (hr)
CA (1) CA2640002A1 (hr)
CY (1) CY1109735T1 (hr)
DE (2) DE102006005016A1 (hr)
DK (1) DK1984006T3 (hr)
EA (1) EA014435B1 (hr)
ES (1) ES2335446T3 (hr)
HK (1) HK1125835A1 (hr)
HR (1) HRP20090684T1 (hr)
MX (1) MX2008009807A (hr)
PL (1) PL1984006T3 (hr)
PT (1) PT1984006E (hr)
RS (1) RS51247B (hr)
SI (1) SI1984006T1 (hr)
UA (1) UA90048C2 (hr)
WO (1) WO2007090569A1 (hr)
ZA (1) ZA200805975B (hr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7832566B2 (en) 2002-05-24 2010-11-16 Biomet Biologics, Llc Method and apparatus for separating and concentrating a component from a multi-component material including macroparticles
US20060278588A1 (en) 2002-05-24 2006-12-14 Woodell-May Jennifer E Apparatus and method for separating and concentrating fluids containing multiple components
US8034014B2 (en) 2007-03-06 2011-10-11 Biomet Biologics, Llc Angiogenesis initation and growth
US20080269762A1 (en) * 2007-04-25 2008-10-30 Biomet Manufacturing Corp. Method and device for repair of cartilage defects
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
PL2259774T3 (pl) 2008-02-27 2013-04-30 Biomet Biologics Llc Sposoby i kompozycje dla wprowadzania antagonisty receptora interleukiny-1
DE102008028684A1 (de) * 2008-06-17 2009-12-24 Kopetzky, Robert, Dr. Blutbeutel
US8460227B2 (en) * 2008-11-17 2013-06-11 Arthrex, Inc. Cytokine concentration system
AU2010237191A1 (en) 2009-04-07 2011-11-03 Velin-Pharma A/S Method and device for treatment of conditions associated with inflammation or undesirable activation of the immune system
US20110052561A1 (en) * 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
CA2772084C (en) 2009-08-27 2016-10-18 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
CN102573856B (zh) * 2009-09-10 2016-10-26 弗莱明·韦林 用于制备微小rna 的方法及其治疗性应用
DE202009017772U1 (de) 2009-12-10 2011-04-21 Orthogen Ag Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid
EP2611456A2 (en) 2010-09-03 2013-07-10 Biomet Biologics, LLC Methods and compositions for delivering interleukin-1 receptor antagonist
DE102010042356A1 (de) * 2010-10-12 2012-04-12 Henke-Sass, Wolf Gmbh Behälter für die Herstellung einer konditionierten Blutzusammensetzung
US9011846B2 (en) 2011-05-02 2015-04-21 Biomet Biologics, Llc Thrombin isolated from blood and blood fractions
US9205110B2 (en) 2012-07-18 2015-12-08 Arthrex, Inc. Enhanced autologous growth factor production and delivery system
DE102012019088A1 (de) * 2012-09-28 2014-04-03 Orthogen Ag Antibakterielle Arzneimittelpräparate
WO2014126970A1 (en) 2013-02-12 2014-08-21 Lacerta Technologies Inc. Serum fraction of platelet-rich fibrin
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
EP2829278A1 (de) * 2013-07-23 2015-01-28 Scientific BioTech GmbH Serum zur Behnandlung von Krankheiten
WO2015081253A1 (en) 2013-11-26 2015-06-04 Biomet Biologics, Llc Methods of mediating macrophage phenotypes
AU2014361728A1 (en) * 2013-12-09 2016-06-02 Cytokine Medical Australia Pty Ltd Apparatus for producing therapeutically active proteins in blood and uses thereof
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation
AU2017313163B2 (en) * 2016-08-17 2019-01-03 Orthogen Ag Anti-ageing pharmaceutical preparation
EP3613424A1 (en) 2018-08-23 2020-02-26 Orthogen AG Novel methods for the production of pharmaceutical agents
DE102021124752A1 (de) 2021-09-24 2023-03-30 Ad Lentus GmbH Autologes Therapeutikum und Verfahren zur Herstellung desselben
CN114146096B (zh) * 2021-11-25 2024-04-02 成都清科生物科技有限公司 一种富含细胞因子的条件血清的制备方法及应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4244437A1 (de) * 1992-12-29 1994-07-28 Horst Dr Med Kief Verfahren zur Gewinnung körpereigener Zytokine
DE19903876B4 (de) * 1999-02-01 2006-09-28 Orthogen Gentechnologie Gmbh Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten
US20020081324A1 (en) * 2002-01-22 2002-06-27 Twine Rebecca Wright Method of treating aging skin and wrinkles using a combination of growth factors that is commercially prepared or derived from one's own blood

Also Published As

Publication number Publication date
MX2008009807A (es) 2008-09-26
EA014435B1 (ru) 2010-12-30
KR20080100425A (ko) 2008-11-18
EP1984006A1 (de) 2008-10-29
RS51247B (sr) 2010-12-31
DE102006005016A1 (de) 2007-08-16
UA90048C2 (ru) 2010-03-25
EP2156841A1 (de) 2010-02-24
PL1984006T3 (pl) 2010-03-31
ATE446100T1 (de) 2009-11-15
DE502007001793D1 (de) 2009-12-03
PT1984006E (pt) 2010-01-20
BRPI0707360A2 (pt) 2011-05-03
EP1984006B1 (de) 2009-10-21
ES2335446T3 (es) 2010-03-26
CA2640002A1 (en) 2007-08-16
AU2007213996A1 (en) 2007-08-16
WO2007090569A1 (de) 2007-08-16
US20090047242A1 (en) 2009-02-19
EA200870222A1 (ru) 2008-12-30
HK1125835A1 (en) 2009-08-21
ZA200805975B (en) 2010-08-25
CN101378768A (zh) 2009-03-04
SI1984006T1 (sl) 2010-02-26
JP2009525297A (ja) 2009-07-09
DK1984006T3 (da) 2010-03-01
CY1109735T1 (el) 2014-09-10
WO2007090569A8 (de) 2008-02-28

Similar Documents

Publication Publication Date Title
HRP20090684T1 (hr) Kondicionirani sastav krvi i metoda za njegovu proizvodnju
JP2009525297A5 (hr)
Chereddy et al. PLGA nanoparticles loaded with host defense peptide LL37 promote wound healing
DeKosky et al. Upregulation of nerve growth factor following cortical trauma
AU2014238304B2 (en) Treatment of inflammatory respiratory disease using biological solutions
AU2014238363B2 (en) Methods and acellular compositions for treating inflammatory disorders
EP2139497A2 (en) Methods for treating nervous system injury and disease
CN105338990A (zh) 治疗炎症性疾病的方法和非免疫原性组合物
JP2023001265A (ja) 長期間の安定性を有する脱細胞化ヒト羊水調製物
KR20100016492A (ko) 올리고글루로네이트 및 올리고갈락투로네이트 조성물
JP2018502600A (ja) 創傷治癒の方法
JP2022180609A (ja) 血小板ペレット溶解物の調製及び神経学的障害の処置のためのその使用
MX2013011040A (es) Metodo para productos terapeuticos encapsulados y usos de los mismos.
CN109844101B (zh) 使用极化巨噬细胞的细胞疗法，用于组织再生
Barussi et al. Intratracheal therapy with autologous bone marrow-derived mononuclear cells reduces airway inflammation in horses with recurrent airway obstruction
Couto et al. The mechanisms underlying the biological response to wear debris in periprosthetic inflammation
William et al. Functional recovery of spinal cord injury following application of intralesional bone marrow mononuclear cells embedded in polymer scaffold-two year follow-up in a canine
Lee et al. Virally inactivated human platelet concentrate lysate induces regulatory T cells and immunosuppressive effect in a murine asthma model
JP2008514633A (ja) 線条体または黒質緻密部における神経学的欠損の治療
Xia et al. Continual deletion of spinal microglia reforms astrocyte scar favoring axonal regeneration
Cheng et al. The effects of intrapleural polyclonal anti-tumor necrosis factor alpha (TNFα) Fab fragments on pleurodesis in rabbits
Mausner-Fainberg et al. Specific blockade of bone morphogenetic protein-2/4 induces oligodendrogenesis and remyelination in demyelinating disorders
JIANG et al. Dose-dependent effects of lanthanum chloride on wear particle-induced aseptic inflammation in a murine air-pouch model
US20170035812A1 (en) Novel cell-derived composition
RU2646793C1 (ru) Средство для собак, обладающее регенеративной активностью